You have read all your free articles, to continue reading subscribe to read the rest of this content.
The U.S. Food and Drug Administration (FDA) has given clearance to start the company's phase III clinical study CONCLUDE in the United States. The study will evaluate the efficacy and safety of the TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis. Already a subscriber Login…
Orexo has announced the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose. OX124, is based on Orexo's drug delivery platform amorphOX and contains a high-dose of naloxone. Already a subscriber Login…
InDex Pharmaceuticals Holding has announced new scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. Cobitolimod haAlready a subscriber Login You have read all your…
Genmab announces that the European Commission (EC) has granted a marketing authorization for DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therAlready a subscriber Login You have read all your…
